Emerging Competition Issues Involving Follow-On Biologics

Darren Tucker joined V&E’s global antitrust practice as a partner in January 2018. Arriving from Morgan Lewis & Bockius LLP, he brings valuable insights to clients regarding competition enforcement and policy issues.

In this article Tucker examines the ways in which pharmaceutical firms have allegedly delayed product entry in violation of the antitrust laws and whether this conduct is likely to occur in the context of biologics and how the antitrust analysis of this conduct may differ for biologics.

Key Contacts

Partner

Darren Tucker

+1.202.639.6553

darrentucker@velaw.com

Related Insights

V&E⁺

6 Things to Know About Handling Contract Disputes in the COVID-19 Era

June 29, 2020
Energy Evolution

Antitrust Issues in Renewable Energy

V&E Antitrust Update

June 22, 2020
Coronavirus: Preparation & Response

Plaintiffs Struggle to Prove Meat and Potatoes of Antitrust Case as COVID-19 Throws Market into Further Disarray

June 4, 2020
V&E⁺

Award-Winning Former Prosecutor, Compliance Officer Brings Unparalleled Experience to V&E

June 4, 2020

This information is provided by Vinson & Elkins LLP for educational and informational purposes only and is not intended, nor should it be construed, as legal advice.